Paratek Pharmaceuticals, Inc. (PRTK)

[faxedreceipts]

Leerink Conference very informative and eye opening and many take home points. These are just a few. I'm tired:

1. No competition from sales representatives of competitive companies because the competition is generic. Generic drugs are 99% never actively promoted by generic companies. Huge advantage for Omad.
No drug in generic space for CAP has as high an efficacy as Omad does.

2. Partnering will not be required the first two years as Paratek focuses on hospitals.

3. Formulary access looks like a very sure thing as this drug will be priced right with flexibility as it will come in oral and IV and no broad spectrum antibiotics for community acquired pneumonia (CAP) have been approved since 1999.

4. Doctors have not had conversations with reps about new CAP antibiotics since 1999! Doctors will want to hear about this drug from the reps or at dinner programs etc. Access to providers will be excellent.